Epidermal growth factor inhibition, a novel pathway to prevent chronic allograft injury

Transplantation

Volumn 98, Issue 8, 2014, Pages 821-827

  Rintala, Jukka M ^a   Savikko, Johanna ^a,b   Palin, Niina ^a   Rintala, Sini E ^a   Koskinen, Petri K ^a,b   Von Willebrand, Eva ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic rejection; Epidermal growth factor; Erlotinib; Kidney transplantation

Indexed keywords

CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ALLOGRAFT INJURY; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DOSE RESPONSE; HISTOPATHOLOGY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MALE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; KIDNEY; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; AORTA; CHRONIC DISEASE; EPIDERMAL GROWTH FACTOR; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TRANSPLANTATION; MALE; QUINAZOLINES; RATS; RATS, WISTAR; TRANSPLANTATION, HOMOLOGOUS;

EID: 84922060826     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000325     Document Type: Article

References (28)

1. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
2. Alpers CE, Davis CL, Barr D, et al. Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Am J Pathol 1996; 148: 439.
3. Savikko J, Kallio EA, Taskinen E, et al. The effect of acute rejection and cyclosporin A-treatment on induction of platelet-derived growth factor and its receptors during the development of chronic rat renal allograft rejection. Transplantation 2002; 73: 506.
4. Pribylova-Hribova P, Kotsch K, Lodererova A, et al. TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int 2006; 69: 1872.
5. Ozdemir BH, Ozdemir FN, Haberal N, et al. Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection. Am J Transplant 2005; 5(4 Pt 1): 766.
6. Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998; 65: 313.
7. Carpenter G, Cohen S. Human epidermal growth factor and the proliferation of human fibroblasts. J Cell Physiol 1976; 88: 227.
8. Blay J, Brown KD. Epidermal growth factor promotes the chemotactic migration of cultured rat intestinal epithelial cells. J Cell Physiol 1985; 124: 107.
9. Sherline P, Mascardo R. Epidermal growth factor-induced centrosomal separation: mechanism and relationship to mitogenesis. J Cell Biol 1982; 95: 316.
10. Wharton W, Leof E, Olashaw N, et al. Mitogenic response to epidermal growth factor (EGF) modulated by platelet-derived growth factor in cultured fibroblasts. Exp Cell Res 1983; 147: 443.
11. Li J, Kim YN, Bertics PJ. Platelet-derived growth factor-stimulated migration of murine fibroblasts is associated with epidermal growth factor receptor expression and tyrosine phosphorylation. J Biol Chem 2000; 275: 2951.
12. Brinckerhoff CE. Morphologic and mitogenic responses of rabbit synovial fibroblasts to transforming growth factor beta require transforming growth factor alpha or epidermal growth factor. Arthritis Rheum 1983; 26: 1370.
13. Takeuchi A, Yoshizawa N, Yamamoto M, et al. Basic fibroblast growth factor promotes proliferation of rat glomerular visceral epithelial cells in vitro. Am J Pathol 1992; 141: 107.
14. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells invitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523.
15. Saad S, Stevens VA, Wassef L, et al. High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int 2005; 68: 985.
16. Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 2004; 66: 1805.
17. Harris RC, Hoover RL, Jacobson HR, et al. Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest 1988; 82: 1028.
18. Helle F, Jouzel C, Chadjichristos C, et al. Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. Am J Physiol Renal Physiol 2009; 297: F191.
19. Francois H, Placier S, Flamant M, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 2004; 18: 926.
20. Sis B, Sarioglu S, Celik A, et al. Epidermal growth factor receptor expression in human renal allograft biopsies: an immunohistochem-ical study. Transpl Immunol 2004; 13: 229.
21. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739.
22. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521.
23. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960.
24. Pore N, Jiang Z, Gupta A, et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006; 66: 3197.
25. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838.
26. Reck M, Mok T, Wolf J, et al. Reviewing the safety of erlotinib in nonYsmall cell lung cancer. Expert Opin Drug Saf 2011; 10: 147.
27. Savikko J, Kallio EA, von Willebrand E. Early induction of platelet-derived growth factor ligands and receptors in acute rat renal allograft rejection. Transplantation 2001; 72: 31.
28. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.